Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of $0.03, $0.08 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $57.34 million versus the consensus estimate of $44.38 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.